Search Results

Avanir is developing its future leadership from within through a program it calls “Leading at Avanir,” which focuses on emotional intelligence and situational leadership components.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.

Avanir Pharmaceuticals, Inc., a pharmaceutical company committed to delivering innovative central nervous system (CNS) solutions, today announced its recognition as one of the 2020 Best Places to Work in Orange County—the only pharmaceutical company listed in the Orange County Business Journal’s 2020 “Best Places to Work in Orange County” Large Employer Category.

Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.

Aurorium, a specialty ingredients manufacturer and materials innovation partner, is pleased to announce the launch of Haelium™ Pharmaceutical Solutions.

Avanir Pharmaceuticals, Inc. and The UCI Paul Merage School of Business are pleased to announce the appointment of two new executives to the School’s Center for Health Care Management and Policy advisory board. Wa’el Hashad, president and CEO of Avanir Pharmaceuticals,

NovaBay® Pharmaceuticals, Inc. and Eyenovia, Inc. have commenced activities under a previously announced co-promotion agreement.

Avanir Pharmaceuticals, Inc. announced that it has reached a resolution of civil, criminal, and administrative claims with the federal government and participating state authorities.

Cycle Pharmaceuticals Ltd today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million.